Long non-coding RNA landscape of patients biopsies from advanced Triple Negative Breast Cancer

The response to specific treatments relies on precise biomarkers, thereby avoiding undesirable toxicities and diminishing the cost. Due to the lack of treatment options in triple-negative breast cancer, it is crucial to search biomarkers with reasonable specificity and sensibility to recognize clusters of patients who could benefit from the cutting-edge oncologist treatments available nowadays. Microarrays were used to detail the global gene expression program to stratified TNBC patients according to TNBCtype software developed by Vanderbilt University and then identified lncRNAs expressed differentially through the TNBC subtypes. FFPE samples were selected from advanced TNBC patients according to clinical criteria for RNA extraction and hybridization on Affymetrix microarrays. We sought to obtain a homogeneous population of patients at stages III and IV to increase the temporal resolution of expression profiles. To that end, we selected patients according to the clinical criteria attended in the National Cancer Institute of Mexico from 2007 to 2010 as described in the paper. Advanced TNBC FFPE samples were selected according to clinical criteria for RNA extracction and hybridization on Affymetrix microarrays. We sought to obtain homogeneous population of patients at stage III and IV in order to increase the temporal resolution of expression profiles. To that end we selected patients according to clinical criteria described in the paper.